The neurotransmitters implicated in the pathogenesis of schizophrenia are dopamine, serotonin, glutamate, and acetylcholine. Cognitive impairment in schizophrenia is partly due to diminished acetylcholine activity in the brain cortex. Patients with schizophrenia and comorbid cognitive dysfunction appeared to show an improvement in their
Galactorrhea With Aripiprazole
Dear Editor: Aripiprazole is a new-generation atypical antipsychotic agent. It is a partial agonist at the dopamine D 2 and serotonin 1A (5-HT 1A ) receptor sites; it is an antagonist at the 5-HT 2 receptor site (1) . Data from the aripiprazole clinical trials suggest that the drug may reduce serum prolactin levels (2) . However, we have observed a case of raised serum prolactin and galactorrhea in association with aripiprazole. To the best of our knowledge, this is the first case of aripiprazole-induced galactorrhea in world literature.
Case Report
Mrs S, aged 36 years, presented with a 2-month history of suspiciousness, withdrawal, and neglect of personal care. She fulfilled DSM-IV criteria for schizophreniform disorder. She was drug-naive for the episode, and was prescribed aripiprazole in a dosage that was titrated from 10 mg daily to 15 mg daily over a period of 2 weeks. At week 3 of aripriprazole therapy, she developed tremor, rigidity, salivation, and bradykinesia, along with simultaneous breast tenderness and a milky discharge from the nipples. Her serum prolactin was found to be elevated to 27 ng/mL (normal range, 1.5 to 19.0 ng/mL). All other investigations, including thyroid profile and brain CT scan, were normal.
The extrapyramidal symptoms resolved with the addition of trihexyphenidyl (4 mg daily). At week 5 of aripripazole therapy the hyperprolactinemia (23.5 ng/mL) and galactorrhea persisted despite a lowered dosage of aripiprazole to 5 mg daily. Aripiprazole was subsequently replaced with quetiapine in a dosage that was raised from 100 mg daily to 300 mg daily over a period of 5 weeks. By week 6 of quetiapine therapy, the patient's serum prolactin had dropped to 6.0 ng/mL, and the breast tenderness and galactorrhea had resolved completely.
Three years previously, Mrs S had a similar episode of psychosis. For 6 months, she received trifluoperazine (15 mg daily) and trihexyphenidyl (2 mg daily) without developing endocrine problems.
The association between aripiprazole and breast tenderness and galactorrhea is irrefutable in our patient; the complaints developed shortly after the introduction of aripiprazole monotherapy, were associated with hyper-prolactinemia, and resolved after the replacement of aripiprazole with quetiapine. The patient had received no other medication that might have explained the adverse effects.
How and why did these adverse effects arise? The partial D 2 agonistic action of aripiprazole implies that the drug will augment dopamine hypoactivity, as is likely in the prefrontal areas, and block dopamine hyperactivity, as is likely in the mesolimbic areas. In patients with schizophrenia, dopamine neurotransmission is probably normal in the nigrostriatal and tuberoinfundibular systems. One might therefore expect aripiprazole to interfere with normal functioning in these pathways, resulting in extrapyramidal symptoms and the consequences of raised serum prolactin. Aripiprazole does indeed cause extrapyramidal symptoms, possibly to the same extent as the typical antipsychotics (2) . Hyperprolactinemia, however, may be either an idiosyncratic response or a dosagedependent adverse effect in sensitive individuals. Future studies should address the epidemiology of endocrinal disturbances with aripiprazole.
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Effects of Rivastigmine in a Case of Residual Schizophrenia
Dear Editor: Among cholinesterase inhibitors, rivastigmine is an acetylcholinesterase and butyrylcholinesterase inhibitor that is widely used in treating Alzheimer's and subcortical vascular dementias, owing to its beneficial pharmacodynamic property.
Combined with antipsychotics, rivastigmine has been found effective in improving negative schizophrenia symptoms (1, 9) . We report a case of residual schizophrenia with predominant negative symptoms that responded to rivastigmine and risperidone.
Case Report
Mrs J is an Indian woman, aged 45 years, with residual schizophrenia (according to ICD-10 criteria) of 6 years' duration. She was treated with risperidone and maintained on 6 mg daily. She presented with marked psychomotor retardation, passivity, lack of initiative, poverty of speech, and poor facial expression. With strong family support, she had maintained good drug compliance and responded to risperidone, which completely controlled her positive symptoms. She developed the presenting complaints during the prior 18 months, despite regularly taking an antipsychotic. Using the clinical interview, patient observation, and additional informant information, we evaluated her baseline negative symptom complex according to the Scale for the Assessment of Negative Symptoms (SANS, 2). We also evaluated her performance in Instrumental Activities of Daily Living (IADL, 3) and on the Satisfaction with Life Scale (SWLS, 4). Further, we administered neurocognitive tests: the Halstead-Reitan Battery (5) for psychomotor speed, attention, and scanning; the Rey Auditory Verbal Learning Test (6); and the Wechsler Memory Scale-Third Edition (7) for learning and memory.
We started the patient on rivastigmine tartrate 1.5 mg twice daily, titrated at monthly intervals to reach a maximum of 6 mg daily in 2 months' time and maintained along with risperidone 6 mg daily. A second SANS evaluation, done after 4 weeks of drug therapy, showed 10% improvement in negative symptoms. The combined treatment of antipsychotic and rivastigmine continued for 6 months, at which time the patient was reassessed. We found a notable drop of 41% from her baseline SANS score. Similarly, her baseline IADL and SWLS scores improved by 36% and 28%, respectively . Neuropsychological tests measured after 6 months showed appreciably better cognitive functions, which were directly related to the improvement in her quality of life.
